WallStreetZenWallStreetZen

NASDAQ: YMAB
Y Mabs Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for YMAB

Based on 6 analysts offering 12 month price targets for Y Mabs Therapeutics Inc

Min Forecast
$7.00+66.67%
Avg Forecast
$14.83+253.17%
Max Forecast
$23.00+447.62%

Should I buy or sell YMAB stock?

Based on 6 analysts offering ratings for Y Mabs Therapeutics Inc.

Buy
Strong Buy
2 analysts 33.33%
Buy
2 analysts 33.33%
Hold
1 analysts 16.67%
Sell
0 analysts 0%
Strong Sell
1 analysts 16.67%
Although YMAB's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates YMAB as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their YMAB stock forecasts and price targets.

YMAB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-21
lockedlocked$00.00+00.00%2025-03-05
lockedlocked$00.00+00.00%2025-03-05
lockedlocked$00.00+00.00%2025-03-05
lockedlocked$00.00+00.00%2024-12-05
Oppenheimer
Bottom 15%
15
BuyInitiates Coverage On$23.00+447.62%2024-11-18

1 of 1

Forecast return on equity

Is YMAB forecast to generate an efficient return?

Company
-48.17%
Industry
146.26%
Market
80.85%
YMAB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is YMAB forecast to generate an efficient return on assets?

Company
-36.96%
Industry
36.38%
YMAB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

YMAB earnings per share forecast

What is YMAB's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
-$1.02
Avg 2 year Forecast
-$1.04
Avg 3 year Forecast
-$0.97

YMAB revenue forecast

What is YMAB's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$82.8M-5.58%
Avg 2 year Forecast
$95.9M+9.4%
Avg 3 year Forecast
$109.4M+24.77%
YMAB's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

YMAB revenue growth forecast

How is YMAB forecast to perform vs Biotechnology companies and vs the US market?

Company
7.63%
Industry
64.61%
Market
10.18%
YMAB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
YMAB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

YMAB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
YMAB$4.20$14.83+253.17%Buy
DRTS$2.71$9.00+232.10%Buy
CDXS$2.33$11.00+372.10%Strong Buy
TVGN$1.01$10.00+890.10%Strong Buy
NGNE$13.03$54.00+314.43%Buy
View Top Biotech Stocks

Y Mabs Therapeutics Stock Forecast FAQ

Is Y Mabs Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: YMAB) stock is to Buy YMAB stock.

Out of 6 analysts, 2 (33.33%) are recommending YMAB as a Strong Buy, 2 (33.33%) are recommending YMAB as a Buy, 1 (16.67%) are recommending YMAB as a Hold, 0 (0%) are recommending YMAB as a Sell, and 1 (16.67%) are recommending YMAB as a Strong Sell.

If you're new to stock investing, here's how to buy Y Mabs Therapeutics stock.

What is YMAB's earnings growth forecast for 2025-2027?

(NASDAQ: YMAB) Y Mabs Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.73%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.6%.

Y Mabs Therapeutics's earnings in 2025 is -$29,666,000.On average, 8 Wall Street analysts forecast YMAB's earnings for 2025 to be -$46,122,541, with the lowest YMAB earnings forecast at -$52,453,085, and the highest YMAB earnings forecast at -$40,696,359. On average, 5 Wall Street analysts forecast YMAB's earnings for 2026 to be -$47,026,904, with the lowest YMAB earnings forecast at -$52,905,267, and the highest YMAB earnings forecast at -$43,409,450.

In 2027, YMAB is forecast to generate -$43,861,632 in earnings, with the lowest earnings forecast at -$57,427,085 and the highest earnings forecast at -$32,104,906.

What is YMAB's revenue growth forecast for 2025-2027?

(NASDAQ: YMAB) Y Mabs Therapeutics's forecast annual revenue growth rate of 7.63% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.18%.

Y Mabs Therapeutics's revenue in 2025 is $87,685,000.On average, 6 Wall Street analysts forecast YMAB's revenue for 2025 to be $3,743,658,092, with the lowest YMAB revenue forecast at $3,615,961,960, and the highest YMAB revenue forecast at $3,809,631,412. On average, 4 Wall Street analysts forecast YMAB's revenue for 2026 to be $4,337,553,629, with the lowest YMAB revenue forecast at $4,056,070,477, and the highest YMAB revenue forecast at $4,558,896,605.

In 2027, YMAB is forecast to generate $4,946,959,000 in revenue, with the lowest revenue forecast at $4,329,640,448 and the highest revenue forecast at $5,196,925,083.

What is YMAB's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: YMAB) forecast ROA is -36.96%, which is lower than the forecast US Biotechnology industry average of 36.38%.

What is YMAB's Price Target?

According to 6 Wall Street analysts that have issued a 1 year YMAB price target, the average YMAB price target is $14.83, with the highest YMAB stock price forecast at $23.00 and the lowest YMAB stock price forecast at $7.00.

On average, Wall Street analysts predict that Y Mabs Therapeutics's share price could reach $14.83 by Mar 21, 2026. The average Y Mabs Therapeutics stock price prediction forecasts a potential upside of 253.17% from the current YMAB share price of $4.20.

What is YMAB's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: YMAB) Y Mabs Therapeutics's current Earnings Per Share (EPS) is -$0.67. On average, analysts forecast that YMAB's EPS will be -$1.02 for 2025, with the lowest EPS forecast at -$1.16, and the highest EPS forecast at -$0.90. On average, analysts forecast that YMAB's EPS will be -$1.04 for 2026, with the lowest EPS forecast at -$1.17, and the highest EPS forecast at -$0.96. In 2027, YMAB's EPS is forecast to hit -$0.97 (min: -$1.27, max: -$0.71).

What is YMAB's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: YMAB) forecast ROE is -48.17%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.